Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DHG2O3
|
|||
| Drug Name |
OT551
|
|||
| Drug Type |
Small interfering RNA
|
|||
| Indication | Age-related macular degeneration [ICD-11: 9B75.0; ICD-10: H35] | Phase 2 | [1] | |
| Company |
Colby Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Activator | [2] |
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00306488) OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration. U.S. National Institutes of Health. | |||
| REF 2 | Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.